Positive results for possible Danish Alzheimer medicine
A Danish candidate drug for the treatment of Alzheimer’s has moved one step closer to the commercial market following positive results in phase II studies.
“Lundbeck’s Lu AE58054 meets primary endpoint in large placebo-controlled clinical proof of concept study in people with Alzheimer’s disease.”
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
